Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

INDUSTRY 17 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 1 Melanoma 1

Interventions

Cyclophosphamide 2067 Radiotherapy 1990 Cisplatin 1856 Carboplatin 1560 Gemcitabine 1454 Paclitaxel 1320 Bevacizumab 1320 pembrolizumab 1238 Docetaxel 1227 Oxaliplatin 1184 Capecitabine 1178 Fluorouracil 1083 Dexamethasone 979 Magnetic Resonance Spectroscopy 971 Nivolumab 936 Rituximab 929 Drug Therapy 915 Surveys and Questionnaires 899 Doxorubicin 845 Etoposide 843 Radiosurgery 816 Blood Specimen Collection 816 Irinotecan 784 Cytarabine 743 fludarabine 726 Leucovorin 684 Surgical Procedures, Operative 640 Lenalidomide 618 Biopsy 594 fludarabine phosphate 569

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × tesetaxel × Clear all

NCT01064713 2018-07-17

Phase II Study of Tesetaxel in Metastatic Melanoma

M.D. Anderson Cancer Center

Phase 2 Completed

17 enrolled 5 charts

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡